Juan C. Vasquez

Assistant Professor

Yale University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Year:

2026

Introduction Gestational age, low birth weight, and overgrowth syndromes are associated with the diagnosis of hepatoblastoma. Previous studies have come to mixed conclusions regarding the contribution of other neonatal intensive care unit (NICU) exposures to hepatoblastoma development. We hypothesized that total parenteral nutrition (TPN) and mechanical ventilation during index NICU admission would correlate with the development of hepatoblastoma. Methods The Pediatric Health Information System (PHIS) was queried for all infants admitted to the NICU with birthdates between 2016 and 2022. From this set, patients subsequently admitted to a PHIS hospital between 2016 and 2023 with a diagnosis code for hepatoblastoma were identified. Billing information was used to calculate the number of days of TPN and mechanical ventilation exposure during NICU hospitalization. Results A total of 258,929 patients were included, with 51 patients diagnosed with hepatoblastoma. Patients with any duration of TPN (OR = 8.51, 95% CI 4.00–18.09) or mechanical ventilation (OR = 8.21, 95% CI 4.30–15.69) developed hepatoblastoma more frequently. Matched conditional logistic regression, on gestational age and birth weight, showed a significant increase in hepatoblastoma for each additional 10 days of TPN (OR = 1.25, 95% CI 1.06–1.50) and mechanical ventilation (OR = 1.21, 95% CI 1.06–1.39). Discussion Leveraging the magnitude of the PHIS, we were able to demonstrate a significant relationship between the duration of exposure to both TPN and mechanical ventilation and the later diagnosis of hepatoblastoma. Although the PHIS lacks granularity in reporting clinical characteristics (e.g., mode and concentration of oxygen delivery and composition of TPN) of these common NICU interventions, future investigations should be directed at the role they may play in hepatoblastoma oncogenesis.

Year:

2025

Glioblastoma (GBM) carries a dismal prognosis, with a median survival of less than 15 months. Temozolomide (TMZ), the standard frontline chemotherapeutic for GBM, is an alkylating agent that generates DNA O 6 ‐methylguanine (O 6 MeG) lesions. Without O 6 MeG‐methyltransferase (MGMT), this lesion triggers the mismatch repair (MMR) pathway and leads to cytotoxicity via futile cycling. TMZ resistance frequently arises via the somatic acquisition of MMR deficiency (MMRd). Moreover, DNA‐damaging agents have been shown capable of increasing tumor immunogenicity and improving response to immune checkpoint blockade (ICB), which has had limited success in glioma. The study of how alkylating chemotherapy such as TMZ impacts antitumor immunity in glioma has been hindered by a lack of immunocompetent models that incorporate relevant DNA repair genotypes. Here, we used CRISPR/Cas9 to generate models isogenic for knockout (KO) of Mlh1 in the syngeneic SB28 murine glioma cell line. MMR KO models readily formed intracranial tumors and exhibited in vitro and in vivo resistance to TMZ. In contrast, MMR KO cells maintained sensitivity to KL‐50, a newly developed alkylating compound that exerts MGMT‐dependent, MMR‐independent cytotoxicity. Lastly, MMR KO tumors remained resistant to ICB, mirroring the lack of response seen in patients with somatic MMRd GBM. The development of syngeneic, immunologically cold glioma models with somatic loss of MMR will facilitate future studies on the immunomodulatory effects of alkylating agents in relevant DNA repair contexts, which will be vital for optimizing combinations with ICB. © 2025 Wiley Periodicals LLC. Basic Protocol 1 : Validation of mismatch repair knockouts and in vitro sensitivity to alkylating agents Basic Protocol 2 : Stereotaxic injection of isogenic SB28 cells in female C57BL/6J mice and in vivo treatment

Year:

2025

DNA damage is fundamental to tumorigenesis, and the inability to repair DNA damage is a hallmark of many human cancers. DNA is repaired via the DNA damage repair (DDR) apparatus, which includes five major pathways. DDR deficiencies in cancers give rise to potential therapeutic targets, as cancers harboring DDR deficiencies become increasingly dependent on alternative DDR pathways for survival. In this review, we summarize the DDR apparatus, and examine the current state of research efforts focused on identifying vulnerabilities in DDR pathways that can be therapeutically exploited in pediatric extracranial solid tumors. We assess the potential for synergistic combinations of different DDR inhibitors as well as combinations of DDR inhibitors with chemotherapy. Lastly, we discuss the immunomodulatory implications of targeting DDR pathways and the potential for using DDR inhibitors to enhance tumor immunogenicity, with the goal of improving the response to immune checkpoint blockade in pediatric solid tumors. We review the ongoing and future research into DDR in pediatric tumors and the subsequent pediatric clinical trials that will be critical to further elucidate the efficacy of the approaches targeting DDR.

Year:

2024

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is caused by loss of function mutations in fumarate hydratase ( FH ) and results in an aggressive subtype of renal cell carcinoma with limited treatment options. Loss of FH leads to accumulation of fumarate, an oncometabolite that disrupts multiple cellular processes and drives tumor progression. High levels of fumarate inhibit alpha ketoglutarate-dependent dioxygenases, including the ten–eleven translocation (TET) enzymes, and can lead to global DNA hypermethylation. Here, we report patterns of hypermethylation in FH-mutant cell lines and tumor samples are associated with the silencing of nicotinate phosphoribosyl transferase (NAPRT), a rate-limiting enzyme in the Preiss–Handler pathway of NAD + biosynthesis, in a subset of HLRCC cases. NAPRT is hypermethylated at a CpG island in the promoter in cell line models and patient samples, resulting in loss of NAPRT expression. We find that FH-deficient RCC models with loss of NAPRT expression, as well as other oncometabolite-producing cancer models that silence NAPRT, are extremely sensitive to nicotinamide phosphoribosyl transferase inhibitors (NAMPTi). NAPRT silencing was also associated with synergistic tumor cell killing with PARP inhibitors and NAMPTis, which was associated with effects on PAR-mediated DNA repair. Overall, our findings indicate that NAPRT silencing can be targeted in oncometabolite-producing cancers and elucidates how oncometabolite-associated hypermethylation can impact diverse cellular processes and lead to therapeutically relevant vulnerabilities in cancer cells. Implications: NAPRT is a novel biomarker for targeting NAD + metabolism in FH-deficient HLRCCs with NAMPTis alone and targeting DNA repair processes with the combination of NAMPTis and PARP inhibitors.

Year:

2024

Collaborators (5)

Leanne Brown

Yale University

UNITED STATES
View details

Emily Christison-Lagay

Yale University

UNITED STATES
View details

Brian Shuch

University of California

UNITED STATES
View details

Matthew Murray

Undergradaute Teaching Assistant

Florida State University

UNITED STATES
View details

David Abramson

Chief, Ophthalmic Oncology

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details